Jefferies analyst Michael Yee is hosting a conference call with life sciences patent lawyer Jacob Sherkow, who said during the call that he believes Amarin has a 50% chance to win its appeal related to its recent loss in litigation related to generic versions of Vascepa.
Source TheFly.com